Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	414.69B
Revenue (ttm)	18.50B
Net Income (ttm)	4.51B
Shares Out	561.61M
EPS (ttm)	8.04
PE Ratio	91.84
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,788
Average Volume	758,819
Open	759.10
Previous Close	758.70
Day's Range	732.00 - 766.70
52-Week Range	570.00 - 801.75
Beta	n/a
RSI	n/a
Earnings Date	n/a

About Triumph Group

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.